Inclusion Criteria:  Patients diagnosed with metastatic or recurrent nasopharyngeal carcinoma are not suitable for radical local treatment. Previous failure of first-line platinum-containing chemotherapy (single drug or combination). Previously diagnosed WHO classification type II or III by histological pathology. At least one measurable lesion (according to RECIST1.1). Age between 18 and 70. Eastern Cooperative Oncology Group (ECOG) 0-1, and life expectation at least 3 months. Enough blood test. Participate voluntarily and sign the informed consent.  Exclusion Criteria:  Previously diagnosed WHO classification type I by histological pathology. Previous use of bevacizumab. Previous use of sorafenib, apatinib, sunitinib, amlotinib and other small molecule --vascular targeting drugs. Previous treatment with PD-1 mmune checkpoint inhibitor. Necrotizing lesions were found within the first 4 weeks, or the risk of massive bleeding. A history of interstitial pneumonia or other autoimmune diseases. Sever infection. Sever heart disease. HIV infection. Allogeneic organ transplantation Malignancy other than nasopharyngeal carcinoma. Pregnancy or breast feeding. Received other test drugs.